WMT

121.93

-2.54%↓

COST

978.68

-1.75%↓

PG

146.71

-3.16%↓

KO

75.98

-2.09%↓

PM

165.95

-3.95%↓

WMT

121.93

-2.54%↓

COST

978.68

-1.75%↓

PG

146.71

-3.16%↓

KO

75.98

-2.09%↓

PM

165.95

-3.95%↓

WMT

121.93

-2.54%↓

COST

978.68

-1.75%↓

PG

146.71

-3.16%↓

KO

75.98

-2.09%↓

PM

165.95

-3.95%↓

WMT

121.93

-2.54%↓

COST

978.68

-1.75%↓

PG

146.71

-3.16%↓

KO

75.98

-2.09%↓

PM

165.95

-3.95%↓

WMT

121.93

-2.54%↓

COST

978.68

-1.75%↓

PG

146.71

-3.16%↓

KO

75.98

-2.09%↓

PM

165.95

-3.95%↓

Search

Lifecore Biomedical Inc

Closed

SectorConsumer defensive

4.11 -5.52

Overview

Share price change

24h

Current

Min

4.08

Max

4.48

Key metrics

By Trading Economics

Income

-7.9M

-10M

Sales

-5.3M

31M

Profit margin

-32.116

Employees

406

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+49.08% upside

Dividends

By Dow Jones

Next Earnings

2 kwi 2026

Market Stats

By TradingEconomics

Market Cap

-21M

220M

Previous open

9.63

Previous close

4.11

News Sentiment

By Acuity

50%

50%

59 / 131 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 mar 2026, 22:42 UTC

Earnings

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mar 2026, 21:40 UTC

Earnings

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mar 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mar 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mar 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 mar 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mar 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mar 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17 mar 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mar 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mar 2026, 22:20 UTC

Earnings

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mar 2026, 22:20 UTC

Earnings

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mar 2026, 22:07 UTC

Earnings

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mar 2026, 22:05 UTC

Earnings

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mar 2026, 22:04 UTC

Earnings

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mar 2026, 22:03 UTC

Earnings

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mar 2026, 21:26 UTC

Earnings

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mar 2026, 21:09 UTC

Earnings

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mar 2026, 21:08 UTC

Earnings

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mar 2026, 21:08 UTC

Earnings

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:07 UTC

Earnings

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:06 UTC

Earnings

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Net $757.2M >ATD.T

17 mar 2026, 20:50 UTC

Market Talk
Major News Events

Energy & Utilities Roundup: Market Talk

Peer Comparison

Price change

Lifecore Biomedical Inc Forecast

Price Target

By TipRanks

49.08% upside

12 Months Forecast

Average 6.5 USD  49.08%

High 9 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forLifecore Biomedical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Sentiment

By Acuity

59 / 131 Ranking in Consumer defensive

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
help-icon Live chat